Rubia, Cerilo A.

HRN: 05-32-30  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/24/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
07/24/2025
08/10/2025
IV
2.25g
Q8H
Ruptured Viscus
Pending Pharmacy Acceptance 

 Indication:  Empirical Escalation    Type of Infection:  Intra-abdominal    Compliance to guidelines: